Effects of neoadjuvant chemotherapy on stage Ⅲ non-small cell lung cancer
Li Tiefu
Jia yu
Chen yunqing
Abstract：Objective To explore effects of neoadjuvant chemotherapy on stage Ⅲ non-small cell lung cancer.Methods From 2006 to 2013,103 patients were randomly divided into pre-operation neoadjuvant chemotherapy group (group A,53 cases) and operation group (group B,50 cases).Group A was given 2 cycles of neoadjuvant chemotherapy,and operation was performed 4 weeks after the last chemotherapy.All 53 cases were given intravenous chemotherapy.The regimens included MVP in 27 cases,NP in 26 cases.Group B was operated without chemotherapy.The post-operative complications,mortality,1,3,5 years survival rate,curative effects were analyzed.Results The resection rate was 86.8％ (46/53)in group A and it was 88.0％ (44/50)in group B.No significant differences of operative complications and mortality were observed between the group A [13.2％ (7/ 53),3.8％ (2/53)],and group B[14.0％ (7/50),4.0％ (2/50)] (P ＞ 0.05).The 1-year、3-year 、5-year survival rate were 86.8％ (46/53),78.0％ (32/41) and 53.8％ (14/26) in group A; they were 68.0％ (34/50),54.8％ (17/31) and 26.1％ (6/23) in group B,respectively.The long-term survival rate in group A was remarkably higher than that in group B (P ＜ 0.05).Conclusions The preoperative neoadjuvant chemotherapy is safe and effective.It can increase the resection rate of the tumor and improve the long-term survival rate with stage Ⅲ NSCLC.
Keywords：Non-small cell lung cancerNeoadjuvant chemotherapyAdverse reaction
Publication Date：2014-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 1458-1460 )